Advertisement · 728 × 90

Posts by Michael Shusterman, MD

Clinician as editor: notes in the era of AI scribes
Every clinician has a strategy. Between patients, before going home, late at night—clinical notes must be written. They are essential for recording patient visits, ensuring continuity of care, arriving at accurate diagnoses, and facilitating communication between doctors, as well as providing medico-legal protection and enabling reimbursement. But these notes are increasingly burdensome to write, thanks in part to the electronic health record (EHR). Artificial intelligence (AI) scribes—computational systems that record clinical encounters and produce narrative summaries—promise much-needed help. Indeed, in many settings, health-care organisations are already adopting this technology. Nevertheless, AI scribes arrive at a moment when the note has already been changing, with legislation 
increasingly granting patients access to their medical records.
Given AI scribes’ promised disruption, it is crucial to consider 
what clinical notes are and what we want them to be. 
Both the clinical encounter and the record of it are fundamentally narrative affairs: the clinical encounter unfolds as a story and the note documents that story. Early 19th-century patient records were long, detailed narratives about particular patients and their histories. But these records promise and limitations.
became increasingly succinct. Forms replaced paragraphs, and shared terminology replaced personal anecdotes; as historian practice of narrative medicine. John Harley Warner explains, there was a shifting “narrative preference for what was universal and precise over what was This trend continues in notes today with their dispassionate style and specialised terminology, ready to be packaged for health-care coders and billers.
A few decades ago, efforts to recentre narrative, especially narrative medicine and narrative-based medicine, emerged to address the depersonalised style of modern medicine exemplified by such notes. So much of medicine i…

Clinician as editor: notes in the era of AI scribes Every clinician has a strategy. Between patients, before going home, late at night—clinical notes must be written. They are essential for recording patient visits, ensuring continuity of care, arriving at accurate diagnoses, and facilitating communication between doctors, as well as providing medico-legal protection and enabling reimbursement. But these notes are increasingly burdensome to write, thanks in part to the electronic health record (EHR). Artificial intelligence (AI) scribes—computational systems that record clinical encounters and produce narrative summaries—promise much-needed help. Indeed, in many settings, health-care organisations are already adopting this technology. Nevertheless, AI scribes arrive at a moment when the note has already been changing, with legislation increasingly granting patients access to their medical records. Given AI scribes’ promised disruption, it is crucial to consider what clinical notes are and what we want them to be. Both the clinical encounter and the record of it are fundamentally narrative affairs: the clinical encounter unfolds as a story and the note documents that story. Early 19th-century patient records were long, detailed narratives about particular patients and their histories. But these records promise and limitations. became increasingly succinct. Forms replaced paragraphs, and shared terminology replaced personal anecdotes; as historian practice of narrative medicine. John Harley Warner explains, there was a shifting “narrative preference for what was universal and precise over what was This trend continues in notes today with their dispassionate style and specialised terminology, ready to be packaged for health-care coders and billers. A few decades ago, efforts to recentre narrative, especially narrative medicine and narrative-based medicine, emerged to address the depersonalised style of modern medicine exemplified by such notes. So much of medicine i…

biases—particularly troubling given medicine’s ongoing research and care disparities. AI-generated summaries can also hallucinate details, making up disturbing interactions if words or phrases resemble training data patterns and inserting inaccuracies. AI can introduce insensitive, incorrect, offensive, or stereotype-based language, gender misattribu- tion, and even diagnostic errors, a set of problems that will be magnified by automation bias—the bias to accept AI decisions and text as more authoritative than human ones.
There are also unique challenges posed by the clinical encounter for AI because of, as machine learning researcher Juan Quiroz and his team put it, the “complex nature of the clinical environment and clinical conversation”. In his experience as a practising clinician who is piloting an AI scribe, one of us (IH) has noticed that AI scribes can miss information from longitudinal clinician–patient relationships and non-verbal communication. They sometimes make speech-to-text transcription errors, confuse the clinician’s story with the patient’s, include details not appropriate to the EHR, use potentially judgemental language, omit important details, add plausible but incorrect information, and overstep their purview, making diagnostic suggestions rather than generating summary. Accents make the speech- to-text transcription less accurate. Most AI scribes today work in limited languages. Some of these issues may improve, but the fundamental problem remains: open notes emphasise notes as interpersonal narrative just as AI scribes seek to automate the task.
To counter these risks of automation, clinicians using AI scribes should view their new role as note editor—a transition best supported by training in editorial and narrative skills. Most immediately, seasoned clinicians will need to reduce transcription errors, odd word choices, extraneous details, and disclosures inappropriate for the record as well as adding missed details and often rewriting AI-ge…

biases—particularly troubling given medicine’s ongoing research and care disparities. AI-generated summaries can also hallucinate details, making up disturbing interactions if words or phrases resemble training data patterns and inserting inaccuracies. AI can introduce insensitive, incorrect, offensive, or stereotype-based language, gender misattribu- tion, and even diagnostic errors, a set of problems that will be magnified by automation bias—the bias to accept AI decisions and text as more authoritative than human ones. There are also unique challenges posed by the clinical encounter for AI because of, as machine learning researcher Juan Quiroz and his team put it, the “complex nature of the clinical environment and clinical conversation”. In his experience as a practising clinician who is piloting an AI scribe, one of us (IH) has noticed that AI scribes can miss information from longitudinal clinician–patient relationships and non-verbal communication. They sometimes make speech-to-text transcription errors, confuse the clinician’s story with the patient’s, include details not appropriate to the EHR, use potentially judgemental language, omit important details, add plausible but incorrect information, and overstep their purview, making diagnostic suggestions rather than generating summary. Accents make the speech- to-text transcription less accurate. Most AI scribes today work in limited languages. Some of these issues may improve, but the fundamental problem remains: open notes emphasise notes as interpersonal narrative just as AI scribes seek to automate the task. To counter these risks of automation, clinicians using AI scribes should view their new role as note editor—a transition best supported by training in editorial and narrative skills. Most immediately, seasoned clinicians will need to reduce transcription errors, odd word choices, extraneous details, and disclosures inappropriate for the record as well as adding missed details and often rewriting AI-ge…

So excited to see this collaboration with brilliant colleagues published in the Lancet today!

Here's our discussion of the humanities skills (esp. narrative + editing) healthcare practitioners will need in the age of AI scribes. @iandarin.bsky.social @mariaa.bsky.social @laurenfklein.bsky.social

1 year ago 30 10 1 0
Preview
OpenNotes Study Aims to Mitigate Scanxiety & Misinformation in Cancer Care - Open Notes Led by OpenNotes, the study, "Mitigating Misinformation & Scanxiety for Cancer Patients," focuses on reducing the stress and confusion patients may face when receiving medical test results electronica...

Health anxiety can be terrifying. 🫠😵‍💫

That’s why #OpenNotes launched a new study to help cancer patients manage "scanxiety"—the stress of awaiting test results.

“We are working towards a future where patients feel more supported.” @cait-desroches.bsky.social

bit.ly/3DjlxQN

#btsm #cancer #medsky

1 year ago 7 6 0 2
Preview
Do Appendiceal Neuroendocrine Tumors Metastasize Post Appendectomy or Right Hemicolectomy? - PubMed Stage IV appendiceal NETs are exceptionally rare, and distant metastases are synchronous in nearly all cases. The risk of metastatic spread after resection of local appendiceal NETs is negligible. Pat...

🦓 Appendiceal NETs - exceedingly rare stage IV

From single-centre at Moffitt
👥124 over 15 years
‼️10 stage IV👉🏻 8 synchronous

Spread is rare - worth putting patients through right hemicolectomy ?

Just in time for @nanets.bsky.social experts statement

pubmed.ncbi.nlm.nih.gov/39705801/ 😃

1 year ago 6 4 1 0
Post image

@nejm.org top 14 most influential articles for 2024

Ponsegromab for cancer #cachexia

Will targeting GDF-15 be a winning strategy in cancer? Sure we will learn more in 2025

1 year ago 4 3 0 0

#Encorafenib + #Ceruximab + mFOLFOX is approved in 1L for BRAFV600e based off #BREAKWATER

- ORR 61% vs 40%
- mDoR: 13.9mos vs 11.1mos
- AEs:GI tox, rash

#cansky #oncsky #gism

1 year ago 8 3 1 0
Preview
Evaluating trastuzumab deruxtecan in patients with gastrooesophageal adenocarcinoma who are ctDNA and HER2 positive: DECIPHER Operable gastrooesophageal adenocarcinoma (GOA) is treated with multimodality therapy which is curative in <50% of patients. Patients in the UK with o…

Good to see our protocol paper for DECIPHER in press at ESMO GO!

ctDNA 🧬 after surgery will detect pts with HER2➕ gastroesophageal #cancer at high risk of recurring

🧬➕ receive TDxD instead of usual post-op chemo

Hope to #cure some micrometastatic cancers 🙏

www.sciencedirect.com/science/arti...

1 year ago 20 5 0 0

Difficult without data. We could not perform analysis due to limited recurrence & survival dataset quality. This will remain provider/institution specific. We dropped 5-FU bolus as an institution, mFOLFOX6 ➡️ mFOLFOX7.

1 year ago 0 0 0 0

Eagerly await the overall survival data, but we also need to see the single arm Nivolumab arm that seems to have disappeared.

1 year ago 3 0 0 0
Advertisement
ASCO Publications

8) TAS‐102 (trifluridine/tipiracil) plus bevacizumab every other week may be more tolerable and induce lower neutropenia rates.

pmc.ncbi.nlm.nih.gov/articles/PMC...

ascopubs.org/doi/10.1200/...

1 year ago 1 0 0 0
Preview
Safety and Efficacy of 7 Days on/7 Days off Versus 14 Days on/7 Days off Schedules of Capecitabine in Patients with Metastatic Colorectal Cancer: A Retrospective Review Micro-AbstractIn an attempt to improve the tolerability of capecitabine in patients with metastatic colorectal cancer (mCRC), an every other week treatment schedule (7/7) is often administered. In thi...

7) Capecitabine can likely be given in the metastatic setting at a fixed dose and 7 days on and 7 days off for many patients. Retrospectively studied in colon cancer (www.clinical-colorectal-cancer.com/article/S153.... Prospective data in breast cancer (ascopubs.org/doi/10.1200/...).

1 year ago 2 0 1 0
Preview
NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial Our findings support use of the NALIRIFOX regimen as a possible reference regimen for first-line treatment of mPDAC.

6) FOLFIRINOX (modified) doses in pancreatic cancer are almost certainly too high for most patients. Lower doses of NALIRIFOX produced identical outcomes. Oxaliplatin 65 and Irinotecan 125-135 is likely more tolerable and equally effective.

www.thelancet.com/journals/lan...

1 year ago 1 0 1 0
Preview
Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study The dose-escalation dosing strategy represents an alternative approach for optimising regorafenib dosing with comparable activity and lower incidence of adverse events and could be implemented in clin...

5) Dose escalation of Regorafenib 80-120-160 is a boards question now as a standard of care. Do not start at 160 mg dosing. Per ReDOS trial.

www.thelancet.com/journals/lan...

1 year ago 1 0 1 0
Preview
Biweekly cisplatin and gemcitabine in patients with advanced biliary tract cancer What's new? Patients diagnosed with biliary tract cancer frequently present with advanced or metastatic disease, for which standard treatment entails an eight-week-long course of weekly administratio....

4) Gemcitabine Cisplatin every other week is more tolerable and has likely similar efficacy to Day 1, 8.

doi.org/10.1002/ijc....

1 year ago 1 0 1 0
Preview
A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-naïve metastatic pancreatic cancer (GI... 4003Background: Evidence-based data is lacking to guide the care of vulnerable older adults with newly diagnosed metastatic pancreatic ductal adenocarcinoma (mPDAC) resulting in extrapolation of the t...

3) In older adults vulnerable adults, every other week Gemcitabine Nab-Paclitaxel should likely be a standard of care based on GIANT trial (ECOG-ACRIN EA2186).

ascopubs.org/doi/10.1200/...

1 year ago 3 1 1 0
Sage Journals: Discover world-class research Subscription and open access journals from Sage, the world's leading independent academic publisher.

2) Gemcitabine Nab-Paclitaxel every other week more tolerable and efficacy similar vs three weeks on.
“A modified regimen of biweekly gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer is both tolerable and effective: a retrospective analysis”

doi.org/10.1177/1758...

1 year ago 1 0 1 0
Advertisement
Preview
Omission of 5-Fluorouracil Bolus From Multidrug Regimens for Advanced Gastrointestinal Cancers: A Multicenter Cohort Study Background: 5-Fluorouracil (5-FU) is a major component of gastrointestinal cancer treatments. In multidrug regimens such as FOLFOX, FOLFIRI, and FOLFIRINOX, 5-FU is commonly administered as a bolus fo...

1) Avoid bolus 5-FU in metastatic regimens.
“Omission of 5-Fluorouracil Bolus From Multidrug Regimens for Advanced Gastrointestinal Cancers: A Multicenter Cohort Study”

doi.org/10.6004/jncc...

1 year ago 0 0 1 0

GI Oncology standard regimen doses are too high for most patients. Retrospective and prospective trials demonstrating benefit of reduced doses or dose escalation. #meded #gionc

1 year ago 5 2 2 0

Great to hear. We’d like to run a survey nationally of practice habits for bolus use. Wondering how best to reach most community oncologists?

1 year ago 2 0 1 0

Interested what the practice among most oncologists is with bolus 5-FU in metastatic setting? How can we raise awareness to remove it from regimens? @oncbrothers.bsky.social @oncothor.bsky.social

1 year ago 2 0 1 0

We obtain MMR and HER2 IHC on all gastro-esophageal, biliary tract, small bowel, and colorectal adenocarcinoma biopsies as a reflex IHC pathway we developed with GI pathology.

1 year ago 0 0 0 0
Post image

#Zanidatamab (bispecific antibody against Her2) now FDa approved for unresectable/metastatic HER2+ biliary tract cancer based #HerizonBTC01:

- Single arm Ph2B study, 20 mg/kg IV Q2W
- mDoR 14.9mos
- mOS 15.5mos
- AEs: Diarrhea, ⬇️EF
- Do you get Her2 IHC on all Bx?

#gism #OncSky #MedSky

1 year ago 3 1 1 0
Preview
Follow-Up Testing and 10-Year Mortality in Patients With Stage II or III Colorectal Cancer This prespecified secondary analysis of the COLOFOL randomized clinical trial examines overall and colorectal cancer–specific mortality rates in patients with stage II or III colorectal cancer who und...

10 year follow-up data from COLOFOL trial demonstrates no benefit to more intensive surveillance in Stage II or III colorectal cancer. How will this change with CTDNA? jamanetwork.com/journals/jam...

1 year ago 0 0 0 0
Preview
Omitting 5-FU Bolus May Reduce Side Effects in Patients With Gastrointestinal Cancers Investigators examined outcomes in patients with gastrointestinal cancers who received fluorouracil (5-FU) through continuous infusion without the bolus component.

ascopost.com/news/septemb...

1 year ago 0 0 1 0
Preview
Study Backs Skipping 5-FU Bolus in Chemo Regimens for Gastrointestinal Cancers No difference in overall survival with versus without bolus, less toxicity without

www.medpagetoday.com/hematologyon...

1 year ago 0 0 1 0
Advertisement
Preview
Skipping 5-FU Bolus Enhances Chemo Tolerance in GI Cancers Dropping 5-FU bolus from multidrug regimens is associated with lower rates of cytopenia in gastrointestinal cancers without affecting survival.

www.medscape.com/viewarticle/...

1 year ago 0 0 1 0
Post image

Excellent accompanying Editorial: jnccn.org/view/journal...

1 year ago 0 0 1 0

Bolus 5-FU should not be used in the metastatic setting with FOLFOX, FOLFIRI, FOLFIRINOX. There will never be a prospective trial studying this, so try to eliminate bolus 5-FU whenever possible. jnccn.org/view/journal...

1 year ago 8 1 3 0
Figure showing treatment of polycythemnia vera.

Figure showing treatment of polycythemnia vera.

Polycythemia vera is a clonal myeloproliferative neoplasm that causes erythrocytosis and is typically associated with a JAK2 gene variant. This narrative review investigates the diagnosis, symptoms, and management of polycythemia vera.

https://ja.ma/3UUmfcY

1 year ago 9 6 1 0
Preview
<em>Journal of Neuroendocrinology</em> | BSN Journal | Wiley Online Library Peptide receptor radionuclide therapy (PRRT) is an effective treatment for both oncological and hormone control and is a widely accepted standard of care treatment for patients with neuroendocrine ne...

You unsure of how to monitor responses in NET patients after PRRT? All these different scans and blood tests confusing? Worry not, this team has you covered...
A must read for all involved in radioligand therapy.
#NETsSky #OncSky
onlinelibrary.wiley.com/doi/10.1111/...

1 year ago 5 2 0 0
Preview
Biomarkers to Inform Prognosis and Treatment for Unresectable or Metastatic GEP-NENs This study provides a guidance document to educate clinicians and patients on biomarkers informing prognosis and treatment in unresectable or metastatic gastroenteropancreatic neuroendocrine neoplasms...

Must read for NET providers - the CommNETs/NANETS statement on NET biomarkers. An extremely useful document, detailing the clinical utility of NET biomarkers after thorough review of the evidence. The short of it is that most are not recommended for routine use.

jamanetwork.com/journals/jam...

1 year ago 4 2 0 0